ev3 Introduces Two New Enhanced Offerings For the Treatment of Peripheral Artery Disease

The SilverHawk® LS-M and MS-M with proprietary MEC™ Technology increases tissue collection capacity, representing an important advancement in Above the Knee treatment of Peripheral Artery Disease
PLYMOUTH, Minn.--(BUSINESS WIRE)--ev3 Inc. (NASDAQ:EVVV), today announced the U.S. launch of the company’s most recent additions to the SilverHawk family of products: the SilverHawk® LS-M and MS-M. These devices are among the latest in plaque excision technology and are designed to treat lesions in arteries above the knee for patients suffering from peripheral artery disease (PAD).
The SilverHawk® LS-M and MS-M include MEC™ (Micro Efficient Compression) Technology, a novel advancement which features precision laser-drilled vent holes in the tip of the catheter. These micro vent holes release fluid pressure, providing more space for the collection of tissue in the tip of the device. This technology has the potential to reduce overall procedure time by enabling physicians to increase tissue collection during plaque removal procedures in large vessels above the knee. In vitro bench test results performed by the company have demonstrated up to a 30 percent increase in tissue capture per insertion compared to the previous device.
press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071218006190&newsLang=en